Streetbeat News

Regulatory

INTC

MU

Intel and Micron Technology are competing in the semiconductor industry. Intel faces challenges with geopolitical issues and partnerships, while Micron is advancing with memory solutions and global expansion. Micron's stock is performing better, with analysts predicting further upside.

Portfolio Pulse from Surbhi Jain

October 16, 2024 | 12:45 pm

NVDA

QQQ

SMCI

SPY

Super Micro Computer, Inc (SMCI) is expanding its liquid-cooled AI server offerings, powered by Nvidia's technology, to enhance energy efficiency and computational power. Despite regulatory challenges, SMCI's stock has seen significant growth over the past year. Investors can gain exposure through ETFs like QQQ and SPY.

Portfolio Pulse from Anusuya Lahiri

October 16, 2024 | 12:38 pm

JAGX

Jaguar Health has launched Gelclair, an FDA-approved prescription product in the U.S. for treating oral mucositis, a painful mouth inflammation often associated with chemotherapy. This marks a significant step for the company in addressing chemo-related side effects.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:38 pm

LH

NOWDiagnostics has partnered with Labcorp to expand access to the first FDA-authorized over-the-counter syphilis test in the U.S. The test will be available in clinical and hospital settings by late 2024, with direct patient access via Labcorp OnDemand in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:23 pm

BDRX

NVAX

VS

Versus Systems shares surged 489% following a $2.5 million investment and licensing deal with ASPIS. Novavax shares dropped 32% after the FDA placed a clinical hold on its vaccine candidates. Biodexa Pharmaceuticals shares rose 245% after successfully appealing Nasdaq's delisting decision.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:23 pm

TOVX

Theriva Biologics has received Orphan Medicinal Product Designation from the European Commission for its product VCN-01, aimed at treating retinoblastoma. This designation could potentially enhance the company's market position and future revenue streams.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:13 pm

ATXS

The European Commission has granted Orphan Medicinal Product Designation to Astria Therapeutics' drug, Navenibart, for the treatment of hereditary angioedema. The Phase 1b/2 trial demonstrated a 90-96% reduction in monthly attack rates with a favorable safety profile.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:13 pm

ALNY

Alnylam Pharmaceuticals has submitted a regulatory application to the European Medicines Agency for Vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy. This submission is based on positive Phase 3 results from the HELIOS-B study, which showed a significant reduction in death and cardiovascular events.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:12 pm

BIAF

bioAffinity's CyPath Lung Cancer Test has received support from new flow cytometry guidelines. VP Jennifer Rebeles contributed to an expert panel that published best practices for rare sample testing in a peer-reviewed journal.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:11 pm

NVAX

Novavax shares declined after the FDA placed a clinical hold on its investigational new drug application for COVID-19-influenza combination and standalone influenza vaccine candidates.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:10 pm